- Home
- MRVI vs PHAT Comparison
MRVI vs PHAT Comparison
Compare MRVI & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRVI | PHAT |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | 416 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 969.8M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MRVI | PHAT |
|---|---|---|
| Price | $7.06 | $11.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $4.13 | ★ $19.83 |
| AVG Volume (30 Days) | ★ 3.1M | 1.2M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.29 | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $185,743,000.00 | $175,110,000.00 |
| Revenue This Year | $12.54 | $93.04 |
| Revenue Next Year | $7.87 | $58.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $1.99 | $8.03 |
| 52 Week High | $7.31 | $18.31 |
Technical Indicators
Market Signals| Indicator | MRVI | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 72.99 | 56.45 |
| Support Level | $3.27 | $9.95 |
| Resistance Level | N/A | $13.17 |
| Average True Range (ATR) | 0.33 | 0.72 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 86.54 | 55.48 |
Price Performance
Historical ComparisonAbout MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.